Protagonist Q1 EPS -$0.19; rusfertide Phase 3 positive, ASCO plenary June 1

Protagonist Therapeutics, Inc

2025-Q1 EPS reported -$0.19 revenue$28,321,000

Cash $697.9M (up from $559.2M Dec 2024); net loss $11.7M (-$0.19/sh) vs income $207.3M in Q1 2024.
Rusfertide Phase 3 VERIFY in PV met primary endpoint (p<0.0001) and all 4 key secondaries; ASCO plenary June 1, conf call June 2.
Icotrokinra Phase 3 ICONIC-LEAD data presented at AAD and WCPD; Phase 2b ANTHEM-UC positive, full data later in 2025.
Revenue $28.3M includes $22.8M rusfertide milestone recognition; vs $255M Q1 2024 with Takeda upfront.
Pipeline: oral IL-17 antagonist PN-881 to enter clinic in 2025; cash runway through at least end of 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.